Blockbuster BeiGene Cancer Drug Adds Another FDA Approval
The FDA approved BeiGene’s Brukinsa as a treatment for advanced cases of follicular lymphoma. It’s the fifth FDA nod for the drug, which has become BeiGene’s top-selling product.
BeiGene’s Phase III Waldenström’s study misses mark, but with a possible silver lining
The Phase III study showed that BeiGene's Brukinsa outperformed AbbVie and J&J's Imbruvica on safety. An analyst wrote that FDA approval on that basis is unlikely, but off-label prescribing is possible. Brukinsa won approval for another blood cancer last month.
presented by
6 Aesthetic Certification Programs That Include Both Theory and Practical Training
Explore top-tier aesthetic certification programs that blend theory with hands-on training — perfect for health care pros ready to elevate their practice